| Similar Articles |
|---|
 |
The Motley Fool
February 25, 2011
Esterhuizen & Sellitti |
12 Small-Cap Biotech Stocks Being Snapped Up by Mutual Fund Investors If you're looking for small-cap biotech investing ideas, the following list might offer some good starting points.   |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Finding a Cure for Cancer: The Option Market's Favorite Ideas What cancer stocks are investors taking seriously?: Allos Therapeutics... China Medical Technologies... Delcath Systems... Myriad Genetics... ZIOPHARM... |
The Motley Fool
January 4, 2012
Rebecca Lipman |
Biotech Ideas: Top Biotech Stocks with Bullish Institutional Trends "Smart money" investors are feeling bullish about these biotech companies: Amyris... VIVUS... InterMune... Savient Pharmaceuticals... Bacterin International... Seattle Generics... Oncothyreon... |
The Motley Fool
December 5, 2011
Rebecca Lipman |
Tech Ideas: 9 Technology Stocks With Insider and Institutional Buying These sophisticated investors feel there is more upside than downside to these names like Merge Healthcare and Level 3 Communications. Do you agree? |
The Motley Fool
December 5, 2011
Alexander Crawford |
Ending HIV/AIDS: Hedge Funds Believe in These 5 Companies Do you think these companies will contribute to a cure? |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
BusinessWeek
April 12, 2004
John Carey |
Gene-Based Therapy: Back To The Couch Recent setbacks show (again) that biotech needs more patience and less ballyhoo |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
The Motley Fool
January 20, 2012
Rebecca Lipman |
Tech Stocks: 2012' s Top Consumer Tech Gadgets Which tech stocks will outperform in 2012? |
The Motley Fool
December 12, 2011
Rebecca Lipman |
China's Landing: Will These Stocks Buck the Trend? Is China cooling more quickly than expected? |
The Motley Fool
December 16, 2011
Rebecca Lipman |
Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most The "smart money" thinks these drug companies have more upside than downside. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
September 16, 2011
Lipman & Esterhuizen |
Investing 101: Stocks Reaching New Highs With Institutional Buying Do you prefer to invest with the trend? If so, the following list may be of interest to you. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
August 22, 2006
Brian Gorman |
NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue. |
The Motley Fool
December 2, 2011
Rebecca Lipman |
Hedge Funds Are Buying These 10 Highly Liquid Dividend Stocks The smart money seems optimistic about these names. Do you think stocks like Acorn Energy and Cognex will move higher? |
The Motley Fool
April 4, 2005
John Reeves |
Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier. |
The Motley Fool
July 26, 2011
Becca Lipman |
Centenarians: Health Services Stocks With an Exposure to Future Health Care Trends Will a generation of centenarians boost the profits of these companies? |
Wired
August 2003
Jennifer Kahn |
The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. |
The Motley Fool
December 8, 2011
Rebecca Lipman |
Emerging Markets: Will These BRIC Stocks Beat Short-Term Uncertainty? The "smart money" thinks these BRIC stocks have the momentum to push even higher -- do you? |
The Motley Fool
December 1, 2005
Brian Gorman |
Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
Pharmaceutical Executive
May 1, 2007
Patrick Clinton |
The Topic of Cancer What will tomorrow's cancer commercialization model really look like? We asked four heavyweights from the world of oncology what they thought. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
August 19, 2011
Cindy Johnson |
12 Biotech Stocks the Insiders Are Buying Folks in the know think these biotech stocks will rise. Should you join them? |
Bio-IT World
June 15, 2003
Barbara Depompa |
Northwest Region Colorado: Biotech Summit in Denver... Utah: A Mecca for Genealogical Research... Washington State: Therapeutics and Diagnostics Niche... |
BusinessWeek
February 12, 2007
Gene G. Marcial |
How Access Helps Treat Cancer Access pharmaceuticals is a tiny biotech trading over the counter. But its two cancer drugs are catching the eye of investors. |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
The Motley Fool
August 10, 2011
Becca Lipman |
American Rebound: Long-Term Investors Remain Bullish on the USA To help you get a perspective on the market's future, we've taken a look at S&P 500 companies experiencing insider buying in addition to institutional buying. |
The Motley Fool
September 21, 2011
Lipman & Esterhuizen |
Biodiesel Stocks: Will Investors Keep Ignoring Biodiesel's Revival? Which biofuel stocks are expected to see the biggest upside? |
The Motley Fool
May 24, 2010
Brian Orelli |
ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse. |
AskMen.com
Jacob Franek |
New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
August 10, 2004
Brian Gorman |
Biotech Cost Control Will the high cost of therapies slow sales in the sector? Investors can avoid problems by paying close attention to companies' pipelines and reimbursement trends. |
The Motley Fool
July 20, 2011
Becca Lipman |
Hedge Funds Love These Undervalued Tech Stocks Interested in finding undervalued technology stocks? Check these out: Blue Coat Systems... Kulicke & Soffa... LTX-Credence... Orbotech... Photronics... TeleNav... Unisys... |
The Motley Fool
March 8, 2011
Esterhuizen & Sellitti |
Going Against the Herd: Insiders Are Buying These Hated Stocks Here's a list of stocks being dumped by the "smart" money that have seen an upsurge in insider buying. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
The Motley Fool
November 16, 2006
Jim Fink |
The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
Managed Care
August 2007
Martin Sipkoff |
Soaring Price of Cancer Drugs Leads Plans To New Approaches Insurers are trying different methods, from pay for performance to promoting preventive care, to hold down cost of chemotherapy drugs. |
The Motley Fool
April 21, 2011
Eben Esterhuizen |
Huge Rebounds Backed by Insider Buying Which rebounding stocks are being fueled by retail buying? |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
The Motley Fool
August 18, 2011
Becca Lipman |
Hedge Funds Love These Undervalued S&P 500 Stocks Big Money thinks the following names are undervalued at current levels -- do you agree? |
The Motley Fool
January 5, 2012
Alexander Crawford |
Financial Stocks: Analysts Expect Bank Profits to Rise 57% in 2012 Do you think these companies in the financial sector will see the large earnings growth analysts expect for the industry? |
